D. Becquart

发表

Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.

R. Pérez-Carrión, Y. Sun, H. Mouridsen, 2004, The oncologist.

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

P. Neven, R. Paridaens, M. Christiaens, 2008, Breast Cancer Research and Treatment.

Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer.

P. Rocmans, P. van Houtte, J. Sculier, 1988, European journal of cancer & clinical oncology.

Original article: A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?

P. V. van Dam, W. Tjalma, I. Vergote, 1999, American journal of obstetrics and gynecology.

Late relapse of a non-seminomatous germ cell tumour from residual mature teratoma.

E. van Marck, P. V. Van Schil, A. V. van Oosterom, 1998, Acta clinica Belgica.

Phase Ii trial of fotemustine in advanced colorectal cancer.

F. Cavalli, H. Bleiberg, B. Gerard, 1990, European journal of cancer.

Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.

M. Aapro, L. Dirix, A. Ardizzoni, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor lysis syndrome in a patient with metastatic merkel cell carcinoma

P. Vermeulen, L. Dirix, A. V. van Oosterom, 1991, Cancer.

Dysgerminoma of the ovary in association with XY gonadal dysgenesis.

I. Vergote, P. Buytaert, D. Becquart, 1983, European journal of obstetrics, gynecology, and reproductive biology.

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences.

J. Klijn, J. de Haes, M. Nooij, 2003, European journal of cancer.

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

J. Klijn, M. Piccart, L. Mauriac, 2000, Journal of the National Cancer Institute.

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, F. Jänicke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

M. Espié, P. Conte, P. Conte, 2009, British Journal of Cancer.

2130 POSTER Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC)

M. Espié, P. Conte, A. Chan, 2007 .

Prostacyclin, thromboxane and prostaglandin F2 alpha; plasma levels in breast cancer.

I. Vergote, A. Herman, G. Laekeman, 1986, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Superior vena cava syndrome as the presenting symptom of an endoluminal metastasis of an osteosarcoma.

L. Dirix, A. V. van Oosterom, R. Vanmaele, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC lung cancer working party (Belgium)

O. Dalesio, P. Rocmans, J. Sculier, 1985, Cancer.

Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium).

P. Rocmans, J. Sculier, J. Klastersky, 1986, Cancer treatment reports.

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

M. Espié, P. Conte, N. Tubiana-Mathieu, 2009 .

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

V. Ganju, P. Conte, N. Tubiana-Mathieu, 2010 .